Supplementary Tables
Supplementary Table 1 
Database combination and gene annotation
In this study, ENSEMBL ID from GENCODE v19 was regarded as the official indicator for further analysis. All databases annotated by other references were re-annotated by an R package biomaRt 3, 4 . Any genes/proteins that failed to annotate unambiguously were excluded from the subsequent analysis.
Methods to evaluate testis-specific genes (TSGs)
In this study, the specificity measure 5 (SPM) was used to evaluate the testis-specific expression pattern.
Each gene expression profile is transformed into a vector :
where n is the number of tissues in the profile. Similarly, a vector can be generated to represent the gene expression in testis:
SPM is the cosine value of the intersection angle θ between vectors and in high dimensional feature space. This variable is calculated by the following expression:
where | | and | | are the length of vectors and , respectively. SPM values range from 0 to 1, with values close to 1 indicating a major contribution to gene expression in a testis (vector ) relative to all other tissues (vector ). Testis-specific genes were defined as genes with SPM higher than 0.9, thus including both testis-restricted and testis-selective genes.
Protein expression quantification in human protein map (HPM)
Normalized spectral counts data were downloaded from http://www.humanproteomemap.org/download.php. Because the SPM distribution calculated from protein spectral counts was similar to the SPM distribution calculated from mRNA abundance (Supplementary Figure 9) , we chose the same cutoff (0.9) to identify testis-specific proteins (TSPs).
Enrichment analysis of testis-specific regulatory elements (TSREs)
In this study, we performed enrichment analysis to evaluate the relationship between the TSREs and the TSGs. Four types of regulatory elements were included in the analysis (promoter, methylation level, ncRNA and enhancer).
Genes from C2 and C4 groups were considered as testis-specific non-coding RNAs (TS-ncRNAs) in our analysis. To avoid ambiguous mapping which derived from overlapping exons of protein-coding genes, we excluded ncRNA that overlapped with the exons of protein-coding genes in the same strand. had beta values in all 15 samples and were used for the definition of the testis-specific methylation site (TSMS). Because of the bimodal distribution of beta value, we could not apply the SPM method. In our study, we defined sites with 25% lower beta value 7, 8 in the testis than in other normal tissues as TSMS.
mRNA expression quantification in TCGA data
We obtained level 3-normalized TCGA RNA-seqV2 expression quantification data from
Firehose at the MIT Broad Institute (https://confluence.broadinstitute.org/display/GDAC/Home, 2014-07-15 release). Twenty cancer types with more than 100 samples were included in the identification of CT genes.
Gene expression was quantified for the transcript models corresponding to the TCGA GAF2.1 using RSEM and normalized within sample to a fixed upper quartile. When defining extremely highly expressed (EE) patterns, expression values of zero were set to one and all data were log2 transformed.
Sample preparation and mRNA expression quantification in the NJMU lung adenocarcinoma (LUAD) tumor/normal data
To validate the extremely high expression (EE) patterns of identified EECTPs, we performed RNA sequencing using Illumina sequencing technology on poly(A)-selected RNA from 24 lung adenocarcinoma samples and their adjacent normal tissues in the NJMU study. Samples were collected from Affiliated Hospitals of Nanjing Medical University. Tissues samples were preserved using RNA-later solution. HE-stained sections from each sample were subjected to independent pathology review to confirm that the tumor specimen was histologically consistent with LUAD (>70% tumor cells) and that the adjacent tissue specimen contained no tumor cells. Total RNA was extracted from cell lines and tissue samples using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted RNA samples were analyzed using an Agilent 2100
Bioanalyzer system (Agilent Biotechnologies, Palo Alto, USA) with the RNA 6000 Nano Labchip Kit. Only samples of high-quality RNA (RNA Integrity Number≥7.5) were used in the subsequent mRNA sample preparation for sequencing. PolyA-minus RNAs were fractionated from total RNA samples and RNA-seq libraries were generated by RNA-fragmentation, random hexamer-primed cDNA synthesis, linker ligation and PCR amplification using a TruSeq TM RNA Sample Prep Kit (Illumina, Inc.). The purified DNA libraries were sequenced with Illumina HiSeq1500 platform (paired-end, 100 base).
Quality control processes followed the same protocols for handling RNA-seq data in normal tissues. Gene expression was quantified for the transcript models corresponding to the GENCODE v19 using RSEM and normalized within sample to a fixed upper quartile.
The definition of EE and activated EECTG/Ps
For each EECTG/EECTP, all samples were classified as activated samples or inactivated samples based on whether their expression exceeded the extremely high expression cutoff ( ) and were recoded as 1 and 0 respectively. For each sample, number of activated EECTPs (count of EECTPs which were coded as 1) was used to represent the degree driven by EECTPs. In our LUAD validation, because the expression of MEIOB of sample 130717001 approaches the extremely-high expression criteria and its co-factor SPATA22 is validated, we consider it as a validated EECTP and include it in the further functional assay.
Obtaining and processing somatic mutation data sets
As described in the result sections, we obtained somatic mutation information to explore the relationship between the EE pattern of EECTPs and somatic mutations. Mutation data were downloaded from the Synapse platform (syn1729383) as "maf" files within the context of the PANCANCER project. Only cancer types with more than 100 samples with both expression and mutation data were included in the analysis, and EECTPs were redefined using data of platform overlapped samples. Impact scores given by the IntOGen-mutations Web discovery tool (http://www.intogen.org/search) were used to evaluate the potential functions of mutations.
Significantly mutated genes (SMGs) of each cancer were obtained from Supplementary Table   4 of a previously published paper 9 . The mutation ratio represented the degree of samples driven by SMG mutations and was calculated as the ratio of the mutation number in SMGs and the mutation number in all genes. Driver summary of papillary thyroid carcinoma were obtained from the Supplementary Table 2 of previous study 10 .
Linear regression was used to evaluate the association between the mutation ratio and activated number of EECTPs. For each SMG, a Wilcoxon's rank sum test was used for the statistical comparison of the activated EECTP number between mutated and non-mutated samples. Fisher's exact test was employed to test mutually exclusive patterns between the SMGs' mutations and EECTPs' EE patterns. P-values were adjusted by Benjamini-Hochberg false discovery rate (FDR-BH). PAM50 subtypes were obtained from the related data from a previous paper 11 .
Obtaining and processing methylation data sets
Seven cancer types had more than 100 samples with both expression and methylation data were included in the analysis, and EECTPs were redefined using data of platform overlapped samples. We downloaded Illumina raw idat-files produced by the Infinium HumanMethylation450 BeadChip Kit of these cancer types from the TCGA data portal Spearman's rank correlation test was used to estimate the correlation coefficient of the expression of CT-ncRNAs and nearby protein-coding CT genes. The cancer types were included in the correlation analysis which had more than ten samples with both expression of CT coding genes and CT-ncRNAs. P-values were adjusted by Benjamini-Hochberg false discovery rate (FDR-BH).
Obtain and processing copy number data
We obtained level 3-focal copy number data from Firehose at the MIT Broad Institute For allele specific copy number analysis, raw .CEL files from genome-wide SNP6.0 microarray data of LUAD samples were preprocessed by R package affy2sv 15 and allele-specific copy number profiling was performed with ASCAT v2.1 16 .
Scores of chromosomal instability scarring (SCINS) were calculated using the following steps of previous study 17 :
1) The proportion of the genome consisting of AiCNA segments, save those segments that encompass a whole chromosome, is calculated.
2) The number of AiCNA segments greater than or equal to 8Mb in length but less than the length of a whole chromosome is counted.
3) The measure of AiCNA segments (S AiCNA ) is calculated by multiplying the proportion obtained in step 1) by the number of segments counted in step 2).
4) The proportion of the genome consisting of CnLOH segments is calculated.
5) The number of CnLOH segments greater than or equal to 4Mb in length, including those that span a whole chromosome, is counted.
6) The measure of CnLOH segments (S CnLOH ) is calculated by multiplying the proportion obtained in step 4) by the number of segments counted in step 5).
7) The measure of AbCNA segments (S AbCNA ) is calculated by counting the number of AbCNA segments greater than or equal to 8Mb in length.
8) The measure of all allelic imbalanced segments (S Ai ) is calculated by summing S AiCNA and S CnLOH .
